Clinical trials
Meibomian Gland Dysfunction trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
62 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 5 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Unknown status | 5 |
| Withdrawn | 5 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 2 |
| Terminated | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lumenis Be Ltd. | 4 |
| University of the Incarnate Word | 4 |
| Sight Sciences, Inc. | 3 |
| Tear Film Innovations, Inc. | 3 |
| University of Alabama at Birmingham | 3 |
| Alcon Research | 2 |
| Cloudbreak Therapeutics, LLC | 2 |
| George Washington University | 2 |
| Johnson & Johnson Surgical Vision, Inc. | 2 |
| Massachusetts Eye and Ear Infirmary | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Meibomian Gland Dysfunction | 62 |
| Dry Eye Syndromes | 40 |
| Blepharitis | 5 |
| Lacerations | 2 |
| Cataract | 1 |
| Chalazion | 1 |
| Cutis Laxa | 1 |
| Meibomitis | 1 |
| Mite Infestations | 1 |
| Pain | 1 |
Trials
Showing 1 to 25 of 62. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.